← All indications
Ureteral Neoplasms
Cancer or tumors of the URETER which may cause obstruction leading to hydroureter, HYDRONEPHROSIS, and PYELONEPHRITIS. HEMATURIA is a common symptom.
Drugs by status
Phase 4 trials (2)
Phase 3 trials (19)
Phase 2 trials (28)
Organizations
Organization Involved with Phase 3 Indications (26)
- Seattle Genetics
- Astellas
- Central European Cooperative Oncology Group
- Medical Research Council
- National Cancer Institute (NCI)
- Canadian Cancer Trials Group
- Cancer and Leukemia Group B (CALGB)
- University of London
- Eastern Cooperative Oncology Group
- Seoul National University
- Southwest Oncology Group
- Spanish Oncology Genito-Urinary Group
- University of Michigan
- University of Toronto
- Groupe D'Etude des Tumeurs Uro-Genitales
- University of Ulsan
- Vanderbilt University
- Medical University of Vienna
- University of Montpellier
- European Organisation for Research and Treatment of Cancer
- Universidad Autonoma de Barcelona
- University of Western Australia
- Department of Veteran Affairs
- Universitaetsklinikum Schleswig-Holstein
- Klinikum Nuernberg - Klinikum Nord
- German Association of Urologic Oncology
Organization Involved with Phase 2 Indications (45)
- Pierre Fabre
- Bristol-Myers Squibb
- Amgen
- AstraZeneca
- Genentech
- Pfizer
- OncoGenex Technologies
- National Institutes of Health (NIH)
- University of Pennsylvania
- Centre Georges Francois Leclerc
- Cornell University
- ECOG-ACRIN Cancer Research Group
- Temple University
- Herbert Irving Comprehensive Cancer Center
- Oregon Health and Science University
- Radboud University
- The Royal Bournemouth Hospital
- Tulane University
- University of Florida
- University of Glasgow
- UNICANCER
- University of Leeds
- University of Milan
- University of Rochester
- University of South Florida
- University of Southern California
- Wake Forest University
- University of Versailles
- Mayo Clinic
- Cardiff University
- +15 more